Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients

This study aimed to evaluate the effectiveness of dalbavancin as sequential therapy in patients with infective endocarditis (IE) due to gram positive bacteria (GPB) in a real-life heterogenous cohort with comorbid patients. A single center retrospective cohort study including all patients with definite IE treated with dalbavancin between January 2017 and February 2022 was developed. A 6-month follow-up was performed. The main outcomes were clinical cure rate, clinical and microbiological relapse, 6-month mortality, and adverse effects (AEs) rate. The study included 61 IE episodes. The median age was 78.5 years (interquartile range [IQR] 63.2–85.2), 78.7% were male, with a median Charlson comorbidity index of 7 (IQR 4–9) points. Overall, 49.2% suffered native valve IE. The most common microorganism was Staphylococcus aureus (26.3%) followed by Enterococcus faecalis (21.3%). The median duration of initial antimicrobial therapy and dalbavancin therapy were 27 (IQR 20–34) and 14 days (IQR 14–28) respectively. The total reduction of hospitalization was 1090 days. The most frequent dosage was 1500mg of dalbavancin every 14 days (96.7%). An AE was detected in 8.2% of patients, only one (1.6%) was attributed to dalbavancin (infusion reaction). Clinical cure was achieved in 86.9% of patients. One patient (1.6%) with Enterococcus faecalis IE suffered relapse. The 6-month mortality was 11.5%, with only one IE-related death (1.6%). This study shows a high efficacy of dalbavancin in a heterogeneous real-world cohort of IE patients, with an excellent safety profile. Dalbavancin allowed a substantial reduction of in-hospital length of stay. Evaluar la efectividad de la dalbavancina como tratamiento de consolidación en endocarditis infecciosa (EI) por bacterias grampositivas en una cohorte heterogénea en vida real. Estudio retrospectivo unicéntrico, incluyendo a los pacientes con EI definitiva tratados con dalbavancina entre enero del 2017 y febrero del 2022. Se realizó un seguimiento de 6 meses. Se evaluaron la tasa de curación clínica, la recaída clínica y microbiológica, la mortalidad a los 6 meses y la tasa de efectos adversos (EA). Se incluyó a 61 episodios de EI. La mediana de edad fue 78,5 años (rango intercuartílico [RI] 63,2-85,2), el 78,7% eran varones, con una mediana del índice de comorbilidad de Charlson de 7 puntos (RI 4-9). El 49,2% presentó EI nativa. El microorganismo más frecuente fue Staphylococcus aureus (26,3%), seguido de Enterococcus faecalis (21,3%